We have read with interest Dr Zielinskis letter and we thank him for his comments.
Different authors stated that partial sternotomy permits excellent visualization of the thymus gland, its vascular attachments, and all peripheral tissues in the mediastinal region limited by the thyroid gland superiorly, between the phrenic nerves laterally, and pericardial sac and mediastinal pleura inferiorly [1] [2] [3] . In our study, we took separate margins for frozen section analysis to make sure no thymic tissue is left behind, and to support our belief that the manubriotomy approach is equal to the sternal approach in the extent of dissection, with the advantage of being less invasive.
Postoperative morbidity was encountered in the sternotomy approach group of our study in six patients out of the 26 patients (23%). We did not differentiate the morbidity in major and minor; we mentioned all abnormal deviations encountered disregarding severity. In a literature review, the operative morbidity in transsternal thymectomy was found to be between 4 and 33% [4] .
In our study, six patients who were operated upon through the transsternal approach had radiological evidence of pneumonitis; in four patients (15.4%) with clinical evidence of chest infection, and in two patients without clinical correlate. This is not surprising because patients with myasthenia gravis face major pulmonary problems as part of their disease process; as the myasthenic forced vital capacities are significantly lower than those for normal subjects. Due to expiratory weakness, cough efficacy is reduced and may lead to postoperative pulmonary complications [5] . The preoperative data of the patients in the sternotomy group of our study have demonstrated those findings in the form of a FVC of 67.2% and a FEV1 of 67% of predicted values.
According to the literature, in transsternal thymectomy the incidence of retention of respiratory secretions is 10%; of atelectasis is 7%. Pneumonia develops in 1-14% of patients, whereas upper airway infections afflict 1.5-35% of surgical patients [4] .
As regards the non-pulmonary complications in our transsternal thymectomy group, they comprised wound infection in two patients with mediastinitis (7.7%), and one patient with phrenic palsy (3.8%). The following incidences of surgical complications are quoted in the literature for transsternal thymectomy: wound infection 1-7%, sternal disruption 1-4%, and injury to the phrenic nerve 0-4.5% [4] .
In conclusion, we would like to emphasize that this comparative study is not trying to discredit the procedure of transsternal thymectomy, but is claiming that there are postoperative advantages of the manubriotomy approach with the same extent of resection which a sternotomy allows. We have read with great interest the report from LopezEncuentra and co-authors addressing the value of Chronic Obstructive Pulmonary Disease (COPD) as a prognostic factor in Non-Small Cell Lung Cancer (NSCLC) [1] . At the conclusion of their analysis on an impressive cohort of 2994 cases of lung cancer, the Authors have concluded that COPD can be considered as a prognostic factor and that there is a clear relationship between the severity of the condition (FEV1%) and survival.
We warmly congratulate the Authors for the clarity of their message and the rigorous methodology they adopted in the analysis, so much so as to insert COPD among the first line prognostic factors in NSCLC. Most interesting is that this is particularly true in early pathological stage (pI) condition, thus confirming COPD to be either an independent prognostic factor, or a completing (and stratifying) criterion within the pathological staging which is unanimously considered among the strongest of prognostic factors.
Along the lines of extreme simplification we would like to comment on this pattern: COPD, in the analysis reported in [1] , has been demonstrated to be a purely 'clinical' prognostic factor. In fact, its detrimental effect on the overall 36-month survival is to be attributed to the diminished functional status (mainly Forced Expiratory Volume in 1 s-FEV1).
In the last decades, a vast amount of literature has been published addressing other, and possibly very important, prognostic factors-those connected with the molecular status of the disease.
The gene expression analysis (microarray) of NSLSC [2, 3] has led to the identification of specific signatures predictive of survival in patients with the same stage of disease. Furthermore, recent expression profile studies [4, 5] demonstrated that gene expression profiles differed in the neoplastic and non-neoplastic tissues of smokers versus non-smokers. To date, it is not known whether these changes are unique to smokers who develop lung cancer or are present in all smokers and whether these changes are associated with the presence of concomitant COPD.
To our best knowledge an analysis of the possible molecular signature of COPD indicating a predisposing status toward the development of lung cancer has never been realised. Moreover, inside the molecular signature of COPD/Lung Cancer patients, an analysis of predisposing factors possibly indicating a worst (or better) prognosis has never been realised either.
In our opinion, it is now time to match and reconcile basic comprehensive information coming from molecular and cellular biology with those coming from clinical experiences (as that reported in [1] ) to foster, in a translational attitude, further investigation.
We are grateful to Spina et al. for their comments concerning our work [1] . In accordance with their hypotheses, it is necessary for the molecular aspect of lung cancer to be studied more thoroughly in general and to deepen into certain subpopulations affected with that neoplasia.
Currently, our sample consisting of 2994 cases of lung cancer from the GCCB-S, is being used to measure the expression of over 30 proteins employing the tissue arrays technology [2] . In doing so, we expect to be able to answer some of the questions raised.
